144 related articles for article (PubMed ID: 28866166)
21. Orodispersible films based on amorphous solid dispersions of tetrabenazine.
Senta-Loys Z; Bourgeois S; Valour JP; Briançon S; Fessi H
Int J Pharm; 2017 Feb; 518(1-2):242-252. PubMed ID: 28007543
[TBL] [Abstract][Full Text] [Related]
22. Supersaturation, nucleation, and crystal growth during single- and biphasic dissolution of amorphous solid dispersions: polymer effects and implications for oral bioavailability enhancement of poorly water soluble drugs.
Sarode AL; Wang P; Obara S; Worthen DR
Eur J Pharm Biopharm; 2014 Apr; 86(3):351-60. PubMed ID: 24161655
[TBL] [Abstract][Full Text] [Related]
23. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
Ruponen M; Visti M; Ojarinta R; Laitinen R
Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
[TBL] [Abstract][Full Text] [Related]
24. Improvement of dissolution property of poorly water-soluble drug by novel dry coating method using planetary ball mill.
Sonoda R; Horibe M; Oshima T; Iwasaki T; Watano S
Chem Pharm Bull (Tokyo); 2008 Sep; 56(9):1243-7. PubMed ID: 18758094
[TBL] [Abstract][Full Text] [Related]
25. Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction.
Chen Y; Wang S; Wang S; Liu C; Su C; Hageman M; Hussain M; Haskell R; Stefanski K; Qian F
Pharm Res; 2016 Oct; 33(10):2445-58. PubMed ID: 27283830
[TBL] [Abstract][Full Text] [Related]
26. Preparation of novel porous starch microsphere foam for loading and release of poorly water soluble drug.
Jiang T; Wu C; Gao Y; Zhu W; Wan L; Wang Z; Wang S
Drug Dev Ind Pharm; 2014 Feb; 40(2):252-9. PubMed ID: 23391363
[TBL] [Abstract][Full Text] [Related]
27. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
28. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions.
Ghebremeskel AN; Vemavarapu C; Lodaya M
Pharm Res; 2006 Aug; 23(8):1928-36. PubMed ID: 16871443
[TBL] [Abstract][Full Text] [Related]
29. Nanocomposite formation between alpha-glucosyl stevia and surfactant improves the dissolution profile of poorly water-soluble drug.
Uchiyama H; Tozuka Y; Nishikawa M; Takeuchi H
Int J Pharm; 2012 May; 428(1-2):183-6. PubMed ID: 22265914
[TBL] [Abstract][Full Text] [Related]
30. Improvement of dissolution and absorption properties of poorly water-soluble drug by preparing spray-dried powders with alpha-glucosyl hesperidin.
Uchiyama H; Tozuka Y; Imono M; Takeuchi H
Int J Pharm; 2010 Jun; 392(1-2):101-6. PubMed ID: 20307634
[TBL] [Abstract][Full Text] [Related]
31. Inclusion of the poorly water-soluble drug simvastatin in mesocellular foam nanoparticles: drug loading and release properties.
Zhang Y; Zhang J; Jiang T; Wang S
Int J Pharm; 2011 May; 410(1-2):118-24. PubMed ID: 20674729
[TBL] [Abstract][Full Text] [Related]
32. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
[TBL] [Abstract][Full Text] [Related]
33. Investigation of a suitable in vitro dissolution test for itraconazole-based solid dispersions.
Thiry J; Broze G; Pestieau A; Tatton AS; Baumans F; Damblon C; Krier F; Evrard B
Eur J Pharm Sci; 2016 Mar; 85():94-105. PubMed ID: 26850682
[TBL] [Abstract][Full Text] [Related]
34. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
35. Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity.
Balakrishnan A; Rege BD; Amidon GL; Polli JE
J Pharm Sci; 2004 Aug; 93(8):2064-75. PubMed ID: 15236455
[TBL] [Abstract][Full Text] [Related]
36. The use of polymer-based electrospun nanofibers containing amorphous drug dispersions for the delivery of poorly water-soluble pharmaceuticals.
Brewster ME; Verreck G; Chun I; Rosenblatt J; Mensch J; Van Dijck A; Noppe M; Ariën A; Bruining M; Peeters J
Pharmazie; 2004 May; 59(5):387-91. PubMed ID: 15212307
[TBL] [Abstract][Full Text] [Related]
37. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054
[TBL] [Abstract][Full Text] [Related]
38. Factors affecting the formation of eutectic solid dispersions and their dissolution behavior.
Vippagunta SR; Wang Z; Hornung S; Krill SL
J Pharm Sci; 2007 Feb; 96(2):294-304. PubMed ID: 17051588
[TBL] [Abstract][Full Text] [Related]
39. Stability study of amorphous valdecoxib.
Ambike AA; Mahadik KR; Paradkar A
Int J Pharm; 2004 Sep; 282(1-2):151-62. PubMed ID: 15336390
[TBL] [Abstract][Full Text] [Related]
40. Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic polymers.
Maniruzzaman M; Rana MM; Boateng JS; Mitchell JC; Douroumis D
Drug Dev Ind Pharm; 2013 Feb; 39(2):218-27. PubMed ID: 22452601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
